Hormone receptor (HR)-positive, HER2-negative, PIK3CA mutated advanced breast cancer

Hormone receptor (HR)-positive, HER2-negative, *PIK3CA*-mutated advanced breast cancer is an incurable molecular subtype of breast malignancy characterized by tumors that express estrogen and/or progesterone receptors, lack overexpression or amplification of the human epidermal growth factor receptor 2 protein, and carry activating mutations in the *PIK3CA* gene

Hormone receptor (HR)-positive, HER2-negative, *PIK3CA*-mutated advanced breast cancer is an incurable molecular subtype of breast malignancy characterized by tumors that express estrogen and/or progesterone receptors, lack overexpression or amplification of the human epidermal growth factor receptor 2 protein, and carry activating mutations in the *PIK3CA* gene Affecting primarily adult women and, less frequently, men, the disease involves breast glandular tissue that has progressed to locally ...

Hormone receptor (HR)-positive, HER2-negative, *PIK3CA*-mutated advanced breast cancer is an incurable molecular subtype of breast malignancy characterized by tumors that express estrogen and/or progesterone receptors, lack overexpression or amplification of the human epidermal growth factor receptor 2 protein, and carry activating mutations in the *PIK3CA* gene Pathophysiologically, somatic gain-of-function mutations in *PIK3CA* hyperactivate the intracellular PI3K/AKT/mTOR signaling pathway, d...

Affecting primarily adult women and, less frequently, men, the disease involves breast glandular tissue that has progressed to locally advanced or distant metastatic stages

Pathophysiologically, somatic gain-of-function mutations in *PIK3CA* hyperactivate the intracellular PI3K/AKT/mTOR signaling pathway, driving uncontrolled cell proliferation, survival, and disease progression while frequently mediating resistance to standard endocrine therapies